NASDAQ:AVDLAvadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have increased by 0.4% and is now trading at $8.02. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.25. The firm had revenue of $12.24 million for the quarter, compared to analyst estimates of $10.25 million. View Avadel Pharmaceuticals' earnings history.

Avadel Pharmaceuticals updated its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

6 analysts have issued 1-year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $6.00 to $18.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $11.92 in the next twelve months. This suggests a possible upside of 48.6% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

News stories about AVDL stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutAvadel Pharmaceuticals.

Avadel Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 6,500,000 shares, an increase of 47.7% from the April 15th total of 4,400,000 shares. Based on an average trading volume of 730,600 shares, the short-interest ratio is presently 8.9 days. Currently, 18.8% of the company's stock are sold short. View Avadel Pharmaceuticals' Current Options Chain.

Some companies that are related to Avadel Pharmaceuticals include Cytokinetics (CYTK), Kiniksa Pharmaceuticals (KNSA), I-Mab (ARQT), MacroGenics (MGNX), Myovant Sciences (MYOV), Aimmune Therapeutics (AIMT), Esperion Therapeutics (ESPR), Mersana Therapeutics (MRSN), Phibro Animal Health (PAHC), INDIVIOR PLC/S (INVVY), Odonate Therapeutics (ODT), Applied Therapeutics (APLT), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA) and NextCure (NXTC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and China Unicom (Hong Kong) (CHU).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (9.55%), Cowen AND Company LLC (4.05%), VR Adviser LLC (2.82%), Invesco Ltd. (1.96%), Tekla Capital Management LLC (1.51%) and Driehaus Capital Management LLC (1.31%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View institutional ownership trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Tekla Capital Management LLC, UBS Group AG, and Investors Asset Management of Georgia Inc. GA ADV. View insider buying and selling activity for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Cowen AND Company LLC, VR Adviser LLC, Invesco Ltd., Driehaus Capital Management LLC, Ghost Tree Capital LLC, Arlington Capital Management Inc., and Bailard Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, and Michael S Anderson. View insider buying and selling activity for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $8.02.

Avadel Pharmaceuticals has a market capitalization of $300.35 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

The official website for Avadel Pharmaceuticals is www.avadel.com.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]